|
C3ORF17 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.70889999718105E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.05969999997235E-06 |
| Normal-vs-Stage2 |
9.425000E-04 |
| Normal-vs-Stage3 |
1.12479999980764E-07 |
| Normal-vs-Stage4 |
5.37529999955488E-07 |
| Stage1-vs-Stage2 |
7.709200E-01 |
| Stage1-vs-Stage3 |
1.138390E-01 |
| Stage1-vs-Stage4 |
1.350820E-01 |
| Stage2-vs-Stage3 |
1.898580E-01 |
| Stage2-vs-Stage4 |
1.531550E-01 |
| Stage3-vs-Stage4 |
8.018200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
9.64919999457692E-09 |
| Normal-vs-AfricanAmerican |
1.482220E-02 |
| Normal-vs-Asian |
3.428100E-04 |
| Caucasian-vs-AfricanAmerican |
3.317200E-01 |
| Caucasian-vs-Asian |
3.657200E-01 |
| AfricanAmerican-vs-Asian |
7.894600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.605100E-04 |
| Normal-vs-Female |
8.07110001055378E-09 |
| Male-vs-Female |
6.547600E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.44659999998542E-06 |
| Normal-vs-Age(41-60Yrs) |
2.51580000054652E-07 |
| Normal-vs-Age(61-80Yrs) |
3.64699999999551E-06 |
| Normal-vs-Age(81-100Yrs) |
1.617730E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.347200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.727200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.728000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.977200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.623800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.399600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.188100E-02 |
| Classical-VS-Follicular |
8.847600E-01 |
| Classical-VS-Other |
7.285000E-01 |
| Classical-VS-Normal |
8.97369999974806E-07 |
| Tall-VS-Follicular |
2.456100E-02 |
| Tall-VS-Other |
3.236800E-01 |
| Tall-VS-Normal |
6.90920000101514E-08 |
| Follicular-VS-Other |
8.192000E-01 |
| Follicular-VS-Normal |
3.770600E-04 |
| Other-VS-Normal |
4.418300E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.19649999996696E-06 |
| Normal-vs-N1 |
4.46739999993007E-07 |
| N0-vs-N1 |
2.129400E-01 |
|
|
